The challenge of improving outcomes in locally advanced cervical cancer

Cervical cancer remains a major cause of death and suffering worldwide, with 90% of cases seen in low-income and middle-income countries (LMICs).1 Cisplatin-based concurrent chemoradiotherapy has been the best available treatment for locally advanced disease since 1999.2 Despite multiple trials testing the addition of other therapies to this backbone, nothing has proven to be better. Although standard treatment cures many patients, 30–50% will relapse, most commonly with distant metastatic disease.